Fact check: Retatrutide Phase 2 trials reported in NEJM show up to 24% body weight loss.

Verdict: mostly true — Trust Score 78/100

The clinical trial statistics presented in the post are highly accurate and correspond to published data in the New England Journal of Medicine (2023), Nature Medicine (2024), and topline Phase 3 results (2025). However, the post is categorized as 'mostly true' rather than 'verified' because it promotes an investigational drug that is not yet FDA-approved, uses AI-generated imagery, and omits critical safety information regarding side effects.

mostly true verification card — Trust Score 78/100
Platform
instagram
Source author
bigrob_h — see all fact-checks of this account
Original post
https://www.instagram.com/p/DW7vdFOkf-R/?igsh=NDkzbWg1YmRoenEz
Verified on
April 18, 2026
Verification ID
SlbmiLgDWhewChopgRqY0g

Original content reviewed

Platform: INSTAGRAM Author: @bigrob_h --- Caption/Description --- RETA TRIALS NEWS JUST KEEPS GETTING BETTER 📈 At this point it’s not one study… it’s a pattern. – Up to ~24% bodyweight loss – Major liver fat reduction – Prediabetes reversal rates that shouldn’t be ignored – Blood pressure dropping double digits – Less hunger… while burning more at rest – Early signals for joint / inflammation improvements This is what happens when you hit multiple pathways at once. Most people try to outwork a broken metabolism. This is fixing the system underneath it. That’s the difference. Watch what happens over the next 2–3 years… this space is going to move fast. If you’ve been paying attention, you already see it. DM “RETA” if you want to understand how people are actually using this 👊 Disclaimer: Educational content only. Not medical advice. Not approved for general use. Speak to a qualified healthcare professional before making any decisions. --- On-Screen Text (OCR) --- New Retatrutide Trial Results Stun! 86% liver fat reduction 72% prediabetes reversal 62% knee osteoarthritis improvement 41% discontinued BP meds 24% body weight loss -14 mmHg blood pressure drop -36% triglyceride reduction -24% total cholesterol reduction Increases metabolic rate at rest Reduces appetite & calorie intake Increases bone mineral density An Incredible New Compound for Health & Longevity Based on data from Phase 2 NEJM trials and Nature Medicine 2024 Published: 2026-04-10T01:55:29.000Z ---VERIFICATION_SUMMARY--- Platform: INSTAGRAM Author: @bigrob_h --- Caption/Description --- RETA TRIALS NEWS JUST KEEPS GETTING BETTER 📈 At this point it’s not one study… it’s a pattern. – Up to ~24% bodyweight loss – Major liver fat reduction – Prediabetes reversal rates that shouldn’t be ignored – Blood pressure dropping double digits – Less hunger… while burning more at rest – Early signals for joint / inflammation improvements This is what happens when you hit mul

Claims analyzed (5)

  1. verified: Retatrutide Phase 2 trials reported in NEJM show up to 24% body weight loss.
    The Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) reported a mean weight reduction of 24.2% at 48 weeks for the 12mg dose.
  2. verified: Retatrutide clinical data indicates an 86% reduction in liver fat and a 72% reversal rate for prediabetes.
    Nature Medicine (2024) reported that 86% of participants on the 12mg dose achieved normal liver fat levels (<5%) at 24 weeks. NEJM (2023) reported that 72% of participants with prediabetes reverted to normoglycemia.
  3. verified: Retatrutide treatment resulted in a 62% improvement in knee osteoarthritis symptoms.
    Topline results from the Phase 3 TRIUMPH-4 trial (December 2025) showed a mean reduction in knee pain of more than 62% (with some metrics showing up to 75.8% reduction).
  4. verified: 41% of participants in Retatrutide trials were able to discontinue blood pressure medications.
    The Phase 2 trial data published in NEJM (2023) confirmed that 41% of participants in the combined 8-mg group discontinued at least one antihypertensive medication.
  5. verified: Retatrutide causes a 14 mmHg drop in blood pressure and a 36% reduction in triglycerides.
    The TRIUMPH-4 Phase 3 trial (2025) reported a 14.0 mmHg reduction in systolic blood pressure. Phase 2 data showed triglyceride reductions of up to 40.6%, making the 36% claim accurate.

Sources consulted (15)

Related verifications

AI-generated analysis. Not a substitute for professional fact-checking.